Neogen’s FY27 Pivot: Dahej On-Track, Battery Sales Set for H2

Neogen Chemicals Limited — Q4 FY26 Earnings Call (held May 18, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “strong financial performance,” “on track,” and a “pivotal inflection point as we enter FY27.”
• They provide confident commissioning/ramp-up timelines and reiterate/expand revenue targets (e.g., FY27 standalone revenue guidance and FY29 consolidated outlook).
• While they acknowledge headwinds (overcapacity, pricing volatility, supply chain disruptions), responses are framed as manageable via pass-through and execution progress.

2. Key Themes from Management Commentary

• Macro/industry headwinds but resilience: Persistent “overcapacity, pricing volatility, and subdued demand,” plus “input cost pressures” and “supply chain disruptions,” yet specialty/differentiated players remain resilient.
• Q4/FY26 operational delivery despite transition costs:
• Q4 revenue INR 247 crore (+22% YoY); EBITDA INR 44 crore (+21% YoY); EBITDA margin 17.8% despite Dahej replacement and tolling-related costs.
• Dahej replacement facility progress + insurance liquidity:
• Dahej replacement plant construction “progressing rapidly,” commissioning “on track for June 2026.”
• Insurance cash received: INR 60 crore tranche in Feb 2026; cumulative on-account claims INR 140 crore; net claim receivable INR 203 crore; working with insurers to expedite final settlement.
• Battery chemicals as the strategic growth engine (Neogen Ionics / battery materials):
• Pakhajan greenfield: mechanical assembly completed; trial run phase started; priorities = “process stabilization, phased capacity ramp-up, and customer qualification.”
• Demand visibility improving for India’s giga-scale ACC ecosystem and international non-FEOC compliant supply chain.
• Customer approvals/audits progressing: provisional approvals from additional global customers; final site audits completed for multiple US-based electrolyte makers awaiting final clearances.
• Project timeline/capex revisions—framed as technology-led optimization:
• They “calibrated execution strategy” leading to revised timelines/costs, but state updated timelines remain “fully aligned with earlier guidance.”
• Dahej Phase 1 budget INR 428 crore (completion Feb 2027).
• Pakhajan Phase 2 revised cost INR 1,367 crore (completion Mar 2027).
• Rationale: “design-led optimization” with “integration of advanced Japanese technologies” and higher localization to reduce import dependence.
• FY27 revenue guidance anchored to ramp-up:
• Management reiterates confidence in standalone FY27 revenue INR 875–950 crore, explicitly stating it is non-battery business (no salt/electrolyte included in that number).
• Battery chemicals revenue potential remains “INR 300 crore plus” with majority in H2 FY27.

3. Q&A Analysis

Theme A: Battery project economics (capex increase, ROCE, returns)

• Core questions
• Why did battery project cost increase by >INR 250 crore? What savings/returns are expected?
• Does ROCE remain 18% after higher capex?
• Management response
• Cost revision attributed to aligning technology to Morita and adding additional 500 MT intermediate facility for sellable intermediates.
• They claim ROCE remains ~18%–20%, stating: “return remains at 18% to 20%” and “ROCE numbers… are at 20% – around 18% to 20%.”
• Assessment
• Strong/definitive framing on ROCE despite capex increase; limited quantitative bridge on how the incremental capex translates into incremental cash flows (no detailed sensitivity).

Theme B: FY27 revenue composition & ramp-up timing (Dahej vs Pakhajan; H1/H2)

• Core questions
• What portion of FY27 standalone guidance includes battery-related sales?
• How much battery chemicals revenue is expected and when (H1 vs H2)?
• How do revised commissioning timelines affect revenue?
• Management response
• Standalone FY27 INR 875–950 crore = non-battery business; explicitly: “there is no salt or electrolyte sales” in that guidance.
• Dahej delay explained as labor shortages; standalone revenue guidance reduced from original ~INR 950–1,000 to INR 875–950.
• Battery chemicals: INR 300 crore+ expected, “mostly towards H2 FY27.”
• They also clarify that Pakhajan Q4 revenue is treated as “backup” depending on approvals/demand.
• Assessment
• Clear separation of standalone vs battery revenue.
• Some hedging remains around approvals and revenue recognition in Q4 (explicitly “not factored” as revenue in some cases).

Theme C: Commodity price pass-through (lithium/bromine) and impact on legacy margins

• Core questions
• Are lithium/bromine prices stabilizing vs prior quarter?
• How do commodity changes affect topline and EBITDA in legacy business?
• What explains inventory/receivables changes?
• Management response
• Bromine: “stabilized a bit”; lithium: “not yet seen a stable lithium price,” but moving toward “normalized” range.
• They emphasize pass-through: “I normally do not factor in commodity price increase into how it will change our topline significantly… most of it is a pass-through.”
• Inventory build explained by renting outside locations and building inventories due to Dahej not fully online; extended slightly to cover sales.
• Assessment
• Consistent narrative: pass-through reduces EBITDA risk; however, they acknowledge other inputs (solvents etc.) may not fully correct.

Theme D: Customer approvals & qualification process (electrolyte/salt; audits; sample representativeness)

• Core questions
• Are samples representative for full capacity?
• When do commercial supplies start (July/August 2026 etc.)?
• How many customers are qualified and what’s the approval timeline?
• Management response
• Samples representative for entire 1,500 MT; audits completed; corrections expected within 1–2 months.
• Commercial supply expected by July/August 2026 for Dahej; Pakhajan approval cycle expected shorter due to Japanese design alignment.
• Domestic giga customers: one already buying small volumes and scaling; another qualified in principle with pilot line and commercial production in 2027; additional customers evaluating vs China.
• Assessment
• Specific dates provided (July/August 2026) and “no need to submit fresh samples unless customer requests,” which is a strong operational signal.

Theme E: Financing, insurance proceeds, liquidity & working capital

• Core questions
• Do they need additional funding in FY27 after insurance and Morita JV equity?
• What explains sharp trade payables increase?
• Will ramp-up delays create liquidity issues?
• Management response
• They state Morita equity ($20m) and insurance are sufficient: “this money is sufficient to take care of completion… we are on track.”
• Trade payables spike explained by negotiating longer credit terms with suppliers while awaiting insurance; suppliers provided special support due to fire-related situation.
• Ramp-up delay repayment schedule delayed similarly: “repayment schedule has already been delayed to the same extent… overall, I do not see a big change… not concerned.”
• Assessment
• Credibility support: they connect repayment timing to SCOD/commissioning and explicitly address liquidity risk.
• Still, they do not provide a full quantified liquidity bridge (cash vs capex vs insurance timing).

Theme F: Capacity utilization, steady-state revenue potential, and consolidated outlook

• Core questions
• What is steady-state revenue on consolidated basis in 3–5 years?
• What utilization ceilings are assumed for salts and electrolytes?
• Management response
• FY28 target: INR 1,100+ crore (full utilization/optimization).
• FY29 consolidated: INR 3,700–4,200 crore (battery side INR 2,500–2,900 crore plus base business).
• Utilization: salt “normally 80%”; electrolyte “can go up to 100%.”
• Assessment
• High confidence but relies on multiple external dependencies (customer ramp-ups, approvals, demand).

4. Guidance / Outlook

Explicit guidance (quantitative)

• Q4 FY26 consolidated performance (reported):
• Revenue INR 247 crore (+22% YoY)
• EBITDA INR 44 crore (+21% YoY)
• EBITDA margin 17.8%
• FY27 standalone (non-battery) revenue guidance:
• INR 875–950 crore (explicitly stated as non-battery business; no salt/electrolyte included)
• Battery chemicals guidance:
• “INR 300 crore plus” revenue potential for Neogen Ionics / battery chemicals in FY27, with majority in H2 FY27
• Project commissioning timelines (quantitative milestones):
• Dahej replacement commissioning: June 2026
• Dahej Phase 1 completion: Feb 2027
• Pakhajan Phase 2 completion: Mar 2027
• Electrolyte commercial manufacturing at Pakhajan: H1 FY27
• Electrolyte salts at Pakhajan: H2 FY27
• Capex (quantitative, revised):
• Dahej Phase 1 budget: INR 428 crore
• Pakhajan Phase 2 revised cost: INR 1,367 crore
• Updated capex schedule aligned with earlier guidance (they claim alignment)

Implicit signals (qualitative)

• Demand visibility improving for India giga-scale ACC ecosystem and international non-FEOC compliant supply chain.
• Customer approvals progressing: provisional approvals, completed audits, and expected corrections completion.
• Operating leverage expected as Pakhajan and Dahej scale up; insurance recoveries expected to support profitability.
• They treat Q4 Pakhajan revenue as “backup” rather than base-case, implying conservatism on timing/approvals.

5. Standout Statements (direct / highly revealing)

• ROCE despite higher capex: “return remains at 18% to 20%” and “ROCE numbers… are at 20% – around 18% to 20%.”
• Standalone vs battery separation (clarity): “INR 875 crore to INR 950 crore is non-battery business. So, there is no salt or electrolyte sales…”
• Dahej commissioning confidence: “commissioning remains on track for June 2026.”
• Pakhajan milestone: “completion of mechanical assembly and successful transition into the trial run phase.”
• Insurance liquidity framing: “net claim receivable stands at INR 203 crore… working closely with insurers towards expediting the final settlement.”
• Battery ramp-up narrative: “Neogen Ionics is at a pivotal inflection point as we enter FY27…”
• Utilization ceilings: “salt would be at 80%… electrolyte… can go up to 100%.”
• Consolidated 3–5 year outlook: FY29 consolidated expected INR 3,700–4,200 crore (based on their projections).

6. Red Flags / Positive Signals

Positive signals
– Clear, repeated timeline specificity (June 2026 commissioning; July/August 2026 commercial supply start for Dahej; H1/H2 split for Pakhajan).
– ROCE target reiterated even after capex revision; management provided a rationale (Morita alignment + intermediate facility).
– Insurance and JV funding explicitly discussed as sufficient for completion; they address liquidity risk directly.

Red flags / watch-outs
– Multiple timeline revisions across calls (Dahej start delay; battery project timeline/cost revisions) while still claiming “aligned with earlier guidance.”
– Pass-through reliance on commodity pricing: while EBITDA impact is said to be limited, management also admits other inputs (solvents etc.) may not correct fully.
– Insurance settlement remains a key dependency: net claim receivable INR 203 crore and final settlement timing is not fully guaranteed.
– Some answers are assertive but not fully quantified (e.g., capex increase → savings/returns bridge lacks detailed numbers).

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Q1 FY26 (Aug 2025): Optimistic but focused on recovery from fire and early JV formation; approvals described as pending customer scheduling.
• Q2/H1 FY26 (Nov 2025): Still optimistic; emphasized resilience and PPAP/approvals progress, but acknowledged delayed electrolyte demand and fire-related costs.
• Q3 FY26 (Feb 2026): Optimistic; “steady recovery” and “on track,” but still highlighted transition costs and insurance claim progress.
• Q4 FY26 (May 2026): More confident/forward-looking—management now speaks in terms of “pivotal inflection point” and provides more concrete commercialization windows (July/August 2026, June 2026 commissioning).
• Classification shift: More Optimistic (confidence and specificity increased; fewer “waiting for customer scheduling” statements, more “audits completed / corrections expected” statements).

b. Tracking Past Commitments vs Outcomes

1) Dahej commissioning / restart timing
– Past statement (Q3 FY26, Feb 2026): “commissioning on track for Q1 FY27.”
– Current (Q4 FY26, May 2026): “commissioning remains on track for June 2026.”
– Outcome: ⏳ Delayed/shifted (Q1 FY27 vs June 2026; still “on track,” but timing moved within the year).

2) Salt approvals timeline
– Past statement (Q3 FY26, Feb 2026): final site audits expected “in Q1 FY27” and commercial supplies expected “in H1 FY27” (electrolyte) with salt in H2.
– Current (Q4 FY26, May 2026): commercial supply start for Dahej expected “by July or August 2026”; Pakhajan salt in H2 FY27; they also say Q4 Pakhajan revenue not factored.
– Outcome: ⏳ Delayed/extended (more granular dates now; still within FY27 but suggests earlier expectations slipped).

3) Battery chemicals revenue guidance
– Past statement (Q3 FY26, Feb 2026): guidance remained INR 400–500 crore battery chemicals part; later in Q3 they also discussed INR 300–500 range.
– Current (Q4 FY26, May 2026): “INR 300 crore plus” with majority in H2 FY27.
– Outcome: ❌ Reduced/softened (from 400–500 to 300+).

c. Narrative Shifts

• From “approvals pending” → “audits completed / corrections expected”:
• Earlier calls emphasized customer scheduling and audit timing uncertainty.
• Now they emphasize “audits completed” and “corrections expected within one or two months.”
• From “battery chemicals as incremental” → “battery chemicals as inflection point”:
• FY27 is framed as transformational (“fundamentally transform our business scale”).
• Standalone revenue framing tightened:
• Current call explicitly separates standalone non-battery guidance from battery chemicals, reducing confusion seen in earlier discussions.

d. Consistency & Credibility Signals

• Medium credibility overall:
• Management provides consistent strategic rationale (non-FEOC, Japanese tech, pass-through model).
• However, timing and revenue guidance have softened (battery chemicals guidance down; commissioning windows shifted).
• They do not fully quantify the “capex increase → ROCE bridge,” though they assert ROCE remains intact.

e. Evolution of Key Themes

• Demand visibility: Improving (more customer audits/approvals referenced).
• Margins: Stable EBITDA margin narrative (17.8% in Q4) but still dependent on lithium price normalization and insurance recoveries.
• Execution risk: Still present but increasingly managed via revised schedules and insurance liquidity.
• Regulatory/approval risk: Still a major driver of timing; management now treats Q4 revenue as backup.

f. Additional Insights (cross-period intelligence)

• A pattern of “alignment with earlier guidance” despite revisions appears: they repeatedly state updated timelines remain aligned, yet they also acknowledge delays (labor shortages, timeline/cost revisions, revenue guidance reduction for standalone).
• Insurance settlement is consistently used to explain margin pressure—this is credible given cash received, but it remains a timing risk because net claim receivable is still large (INR 203 crore).
• Management’s confidence increases as milestones move from “pending” to “completed,” suggesting the narrative is milestone-driven rather than purely demand-driven.